Navigation Links
NicOx Reports Results for the First Three Quarters of 2008
Date:10/22/2008

es its liquid assets principally to cover research and development expenses, expenses relating to the development of relationships with pharmaceutical companies, with a view to encouraging new partnerships, and corporate expenses related to general and administrative and promotional activities. NicOx expects its operating expenses to continue to increase very strongly over the coming financial years, as a result of the anticipated expenses related to the clinical development and the launch preparation activities for its drug candidate naproxcinod, which is currently in phase 3 clinical development.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, widespread eye diseases and Chronic Obstructive Pulmonary Disease (COPD).

NicOx S.A. is headquartered in France and is listed on the Euronext Paris Stock Exchange (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assum
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
2. NicOx Announces Departure of Damian Marron for CEO Position
3. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
4. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
5. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
6. NicOx Opens U.S. Headquarters in New Jersey
7. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
8. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
11. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2009)... Dendreon Corporation (Nasdaq: DNDN ) announced today that ... shares of its common stock at a price to ... granted to the underwriters a 30-day option to purchase ... to cover overallotments, if any. The offering is ... customary closing conditions. ,, J. P. Morgan Securities Inc. ...
(Date:12/10/2009)... Eye Institute (NEI), a division of the National Institutes of ... to help fund its development of a non-invasive, passive diffusion-based ... ... Salt Lake City, UT (PRWEB) December 10, ... the National Institutes of Health (NIH), awarded a $2.18 million ...
(Date:12/10/2009)... - YM BioSciences Inc. (NYSE Amex: YMI ... company that identifies and advances a diverse portfolio ... development, today provided an update on the proposed ... Cytopia Ltd. into YM, details of which were ... directors of Cytopia has unanimously recommended that its ...
(Date:12/10/2009)... Dec. 10 Vivakor, Inc. (OTC ... has entered into an exclusive, $5 million ... International, Inc. ( www.regeneca.com ). The ... to a new cutting-edge nutraceutical formulation developed ... of future formulations by Vivakor for Regeneca. ...
Breaking Biology Technology:Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3
... TUSTIN, Calif., Nov. 29 AMDL, Inc. ... in Shenzhen,Jiangxi and Jilin China, through its ... an international biopharma company and today,announced that ... from the,Chinese Federation of Industry and Commerce ...
... Pfizer Assets, Talent, ANN ARBOR, Mich., Nov. 29 ... the state of Michigan through the 21st Century,Jobs Fund. ... Michigan loan,fund with a low interest rate, is intended ... the region. Job creation is vital for,consideration for approval ...
... RAPIDS, Mich., Nov. 29 The Center for ... first member of the Xceed,Molecular (http://www.xceedmolecular.com ; ... CMM is the first US site to offer ... giving researchers an,important new tool in disease investigation ...
Other Biology Technology:AMDL's Chinese Subsidiary Wins Key Brand Excellence Award for Anti-Aging Treatment 2Ann Arbor SPARK Receives $3.75M from Michigan's Company Formation & Growth Fund 2Ann Arbor SPARK Receives $3.75M from Michigan's Company Formation & Growth Fund 3Center for Molecular Medicine Offers Xceed Ziplex(TM) Services to Research Community 2
(Date:12/14/2009)... The most comprehensive study to date of the ... appendages may provide important clues to how similar regeneration ... the School of Science at Indiana University-Purdue University Indianapolis ... amputated limbs of axolotls, a type of salamander that ... any level of amputation, with the hope that this ...
(Date:12/14/2009)... feature of humans. That,s until examples of tool use came ... of other mammals. Now, a report in the December 14th ... adds an octopus to the growing list of tool users. ... that the researchers call stilt walking. In it, the soft-bodied ... its eight arms rigid, and raises the whole assembly to ...
(Date:12/14/2009)... preventing some of the stresses of open surgery on the ... organ dysfunction. Laparoscopy is a type of surgery in the ... By adding another gas to the carbon dioxide used to ... Medical Center have found they can preserve more normal blood ... (ENO) helped to open blood vessels and keep blood flowing, ...
Breaking Biology News(10 mins):IUPUI researchers tackle protein mechanisms behind limb regeneration 2Tool use in an invertebrate: The coconut-carrying octopus 2Gas improves blood flow and organ status during minimally invasive surgery 2Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 1Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 2Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 3Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 4Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 5Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 6Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 7Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 8Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 9Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 10Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 11Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 12Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 13Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 14Dr James OConnell Named J H Kanter Prize Laureate 54148 1Dr James OConnell Named J H Kanter Prize Laureate 54148 2Dr James OConnell Named J H Kanter Prize Laureate 54148 3German District Court Rules in Smith 26 Nephews Favor in Patent Infringement Case 54146 1German District Court Rules in Smith 26 Nephews Favor in Patent Infringement Case 54146 2German District Court Rules in Smith 26 Nephews Favor in Patent Infringement Case 54146 3
... a violin to produce strong, elegant notes, researchers at ... outside of the body,s killer immune system cells which ... cells in superb infection- and disease-fighting condition. , In ... Immunology , the researchers describe their discovery of seven ...
... The Journal of Experimental Biology are pleased ... of Sydney is the winner of this year,s JEB ... 28th November in The Journal of Experimental Biology ... the contribution of an outstanding young scientist to an ...
... differentiations in the metabolic make-up of the human ... in the open-access journal PLoS Genetics . ... Karsten Suhre, has conducted a genome-wide association study ... in the breakdown of fats. The resulting differences ...
Other Biology News:Wistar scientists find key to keeping killer T cells in prime shape for fighting infection, cancer 2Wistar scientists find key to keeping killer T cells in prime shape for fighting infection, cancer 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 3Study identifies genetic variants giving rise to differences in metabolism 2
... Reagent , 2 x 50 ml 10X TBST Wash ... 0.2 ml BL21 glycerol stock , 0.2 ml BLT5403 ... 1010 pfu T7Select Positive Control Lysate , 1010 ... HRP Conjugate , 2 ml T7Select S-protein , ...
...
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: